Company intelligence / Profile preview

Yoshindo

Toyama, Toyama, Japan

Ownership: Private
Development stage: Other

Overview

Yoshindo is a leading Japanese pharmaceutical and biotechnology company engaged in the development, manufacture, and commercialization of generic drugs, biopharmaceuticals, and biosimilars. Recent approvals and launches include Ustekinumab biosimilar for psoriasis vulgaris and psoriatic arthritis. The company partners with Biocon Biologics for ustekinumab and denosumab biosimilars in Japan, and previously with Lupin for etanercept biosimilar. Yoshindo is actively commercializing multiple products in the Japanese market, some through key strategic joint ventures.

Therapeutic areas: ImmunologyRheumatologyDermatologyPulmonologyNeurology
Modalities: Small moleculeBiosimilarMonoclonal antibodyFusion protein
Industry: Biotech

Partnerships

Biocon BiologicsLupin Limited

Beyond the preview

Go deeper on Yoshindo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yoshindo.

Explore the full profile